Dorzolamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dorzolamide: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Dorzolamide (Trusopt®/Cosopt®) is a topical carbonic anhydrase inhibitor used globally to lower intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, with 1 clinical trial and no published literature currently supporting this specific direction. The mechanistic rationale is strong, as both conditions share elevated IOP as the central pathological driver, making this more a precision extension than a true therapeutic leap.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma and ocular hypertension |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from formal regulatory sources in this Evidence Pack. Based on known pharmacological information, Dorzolamide is a topical carbonic anhydrase inhibitor (CAI) that selectively inhibits multiple carbonic anhydrase isoforms expressed in the eye — specifically CA1, CA7, CA12, and CA14. By blocking these enzymes in the ciliary body epithelium, dorzolamide reduces aqueous humor secretion, thereby lowering IOP. It is marketed as Trusopt® (monotherapy) and as Cosopt® (fixed combination with the beta-blocker timolol maleate).
Primary hereditary glaucoma is a genetically determined optic neuropathy in which IOP elevation — arising from impaired trabecular meshwork drainage — causes progressive retinal ganglion cell loss and visual field damage. The underlying pathological target (elevated IOP) is identical to that addressed by dorzolamide in open-angle glaucoma. Because dorzolamide reduces IOP by suppressing aqueous humor production regardless of whether the drainage defect is genetic, structural, or acquired, its mechanism transfers directly and coherently to hereditary subtypes. This is not a mechanistic stretch — it is application of the same drug to a pathologically congruent condition defined by a different etiological root cause.
This is further supported by clinical practice: primary hereditary (congenital) glaucoma frequently presents in infancy and childhood, and pharmacological IOP reduction with CAIs is a recognized bridging and adjunct strategy when surgical intervention is incomplete or has failed. The sole Phase 2 trial identified in this Evidence Pack (NCT01527682) tested latanoprost and dorzolamide directly in primary pediatric glaucoma — which encompasses hereditary forms — confirming that this drug has already been evaluated in populations that largely overlap with the predicted indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01527682 | Phase 2 | Completed | 37 | Assessed the ocular hypotensive effect and safety of latanoprost and dorzolamide in primary pediatric glaucoma (including congenital/hereditary forms) refractory to surgical procedures; evaluated whether medical therapy could achieve clinically meaningful IOP reduction in this high-need population |
Literature Evidence
Currently no related literature directly addressing dorzolamide in primary hereditary glaucoma is available.
Safety Considerations
The key warnings and contraindications data for Dorzolamide were not captured in this Evidence Pack.
- Pharmacological Targets: Dorzolamide acts on carbonic anhydrase isoforms CA1, CA7, CA12, and CA14 (Human). Systemic absorption of topically applied dorzolamide is documented; patients with sulfonamide allergy may be at risk given the sulfonamide chemical scaffold.
Please refer to the Trusopt® or Cosopt® package insert for complete prescribing information, including warnings on renal/hepatic impairment, sulfonamide hypersensitivity, contact lens use, and concomitant oral CAI use.
Conclusion and Next Steps
Decision: Hold
Rationale: Dorzolamide has a compelling mechanistic case for use in primary hereditary glaucoma — the IOP-lowering mechanism is directly applicable — and Phase 2 pediatric evidence exists. However, the drug is currently unregistered in India (0 CDSCO approvals), the available trial is indirect (pediatric glaucoma broadly, not specifically hereditary subtypes), and no Indian-specific or hereditary-glaucoma-specific literature has been identified. Advancing without regulatory presence and targeted evidence is premature.
To proceed, the following is needed:
- CDSCO registration of dorzolamide (Trusopt® or generic equivalent) in India as a prerequisite for any repurposing pathway
- Full MOA documentation from DrugBank and Indian prescribing information (package insert warnings and contraindications)
- Subtype-specific evidence: A prospective study or registry analysis in primary hereditary glaucoma patients (e.g., CYP1B1 mutation carriers, primary congenital glaucoma) explicitly evaluating dorzolamide IOP response
- Pediatric safety profile for the Indian population, particularly for long-term carbonic anhydrase inhibition in children with genetic glaucoma
- Genetic subtyping to confirm IOP-dependent (trabecular) rather than IOP-independent pathology in the target cohort, ensuring mechanistic alignment
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.